RU2137488C1 - Rosewort as antibacterial agent - Google Patents

Abstract

FIELD: medicine, phytotherapy. SUBSTANCE: invention proposes to use decoctions and extracts of rosewort (Rhodiola rosea L.) as an antibacterial agent. Preparations exhibit inhibitory effect of bacterium growth, enhance effectiveness of treatment of suppurative-inflammatory sicknesses. EFFECT: enhanced effectiveness of an agent. 4 tbl, 3 ex

Description

 The invention relates to medicine, to drugs and is intended for antibacterial effects on pathogenic microflora in the treatment of purulent-inflammatory diseases.

 The use of antibiotics as an antibacterial agent ("Medicines used in medical practice in the USSR" under the editorship of M. A. Klyuyev - M .: Medicine 1991) is known. One of the main disadvantages of antibiotic antibiotic therapy is the high allergization of the population and the frequent individual intolerance to these drugs. Also a significant problem remains the immunosuppressive effect of antibiotics, especially pronounced when using shock and over-shock dosages (M. D. Mashkovsky "Medicines". - M .: Medicine, 1993). Along with this problem, the issue of adequate immunocorrective therapy is also not resolved.

 It is known the use of drugs from the group of extracts of the thymus and its chemical analogues for the treatment of purulent-inflammatory diseases ("Inflammatory diseases of the maxillofacial region and neck" under the editorship of Shargorodsky. -M .: Medicine, 1985).

 However, these drugs have a number of disadvantages: for the application of most of them, a parenteral route of administration is necessary. Like all protein compounds, they are highly allergenic and there is a group of patients who are contraindicated in the administration of thymus preparations. Given the direct impact on the immune system, these drugs should be used only under the supervision of a specialist in the field of immunology with a mandatory study of immunity indicators.

 The objective of the invention is the expansion of the arsenal of drugs.

 The problem is solved in that rhodiola rosea is used as an antibacterial agent.

 Rhodiola rosea is a medicinal substance from the group of natural adaptogens. Rhodiola rosea has a pronounced immunocorrective effect, is easily tolerated by patients, has an enteric route of administration, has no identified contraindications, does not have allergenic properties, and has no consequences after use (Saratikov AS "Rhodiola rosea is a valuable medicinal plant." Tomsk, 1987) .

 The antibacterial activity of Rhodiola rosea was first detected. The effectiveness of the antibacterial action of Rhodiola rosea is comparable to the action of broad-spectrum antibiotics.

 Unlike other natural adaptogens (ginseng, eleutherococcus, aralia, zamanicha), which cannot be used in the phase of the acute inflammatory process, as they penetrate the microorganism, they act on it like on the macroorganism, causing an increase in pathogenicity and virulence of the pathogen, the use of Rhodiola rosea in combination with antibiotics increases the effectiveness of the treatment of purulent-inflammatory diseases.

In the experiment, the sensitivity of microflora was determined by the method of disks to 15, 30, 45% decoctions of Rhodiola rosea, 15% solution of oxacillin (standard disk) and a mixture of 15% decoction of Rhodiola rosea and 15% solution of oxacillin in equal proportions. Standard pathogenic strains of Staphyllococcus Aureus 668 were used. E.Coll 1240, Streptococcus epidermidis isolated from a patient with phlegmon of the mouth, seeded on Agar-Agar with a "lawn" of 6 Petri dishes for each drug substance in each of 3 performed series of experiments. The cups were incubated at a temperature of 37 ^o C for 24 hours. In the table. 1 shows the average values of zones (in mm) free of bacterial growth.

 The table shows that with an increase in the concentration of rhodiola rosea broth, the antibacterial activity of the drug does not change. The antibacterial activity of the drug Rhodiola rosea is approaching the antibacterial activity of oxacillin. With respect to Escherichia coli, the antibacterial effect is also pronounced, although to a lesser extent. A mixture of drugs has a more pronounced antibacterial effect, despite a halving of the concentration of each of them.

 Thus, the drug Rhodiola rosea has antibacterial activity. The effectiveness of the antibacterial effect of the drug Rhodiola rosea is comparable to the action of broad-spectrum antibiotics.

 The study of the systemic effect of Rhodiola rosea was carried out on a model of acute lower jaw osteomyelitis (A.S. N 1746396, publ. 07.07.92, Bull. N 25). For the experiment, 40 male Wistar rats weighing approximately 250 g were used. Subperiosteally, they introduced a culture of pathogenic St.aureus at the rate of 2 billion cells per animal. There were 4 groups: the first group of animals received 30% Rhodiola rosea extract, 1 ml orally daily: the second group received bicillin-5 intramuscularly, 50,000 units, once every 5 days; the third group received a 30% extract of Rhodiola rosea, 1 ml per day, and bicillin-5 intramuscularly, 50,000 units, once every 5 days; the fourth group received a 30% alcohol solution of 1 ml orally 1 time per day and a 0.25% solution of novocaine intramuscularly 1 time in 5 days, 1 ml each (control).

 According to clinical observations, all animals developed acute purulent inflammation of the periandibular soft tissues in the form of abscesses in the injection zone of staphylococcus for 2-3 days. The most favorable inflammatory process occurred in animals of the third group - all acute inflammatory phenomena stopped in 5–6 days, in animals of the second group - in 6–7 days, in animals of the first group –– 7–8 days and in animals of the fourth group –– 7 -10 days. In three rats of the first group, in three rats of the second group, in five rats of the third group, and in one rat of the fourth group, the chronic process, accompanied by destruction of the jaw, did not develop.

 In the table. Figure 2 shows the size of the zone of destruction of the lower jaw in rats, measured on 28 days after the start of the experiment.

 Thus, in an in vivo experiment, it was found that in the treatment of rats suffering from acute inflammatory disease of the maxillofacial region, the use of Rhodiola rosea as an antibacterial agent is effective. The greatest effect was obtained from the use of Rhodiola rosea together with bicillin.

 The drug Rhodiola rosea was tested in the clinic of maxillofacial and plastic surgery of St. Petersburg State Medical University. Acad. I. P. Pavlova in the treatment of 30 patients with acute inflammatory diseases of the maxillofacial region aged 29 to 66 years, both sexes.

 Of these, 16 patients received the drug in the form of a 10% extract inside of 10 drops, in severe cases - 10 drops in the morning and afternoon. In 4 patients, the drug was used in the form of a 15% decoction for washing the wounds after drainage with external access 1 time per day. In 10 patients, the drug Rhodiola rosea was used in a complex manner - the drug was taken orally and the local use of the drug was combined.

 In 5 patients with a favorable prognosis of the disease, Rhodiola rosea was not combined with antibiotics and acted as a mono-antibiotic therapy. In 25 patients, the drug was combined with the use of antibiotics in medium therapeutic dosages.

 The following studies were performed in patients: clinical blood test, immunological examination, general urine analysis. With topical use of the drug Rhodiola rosea, an additional bacteriological study of the wound discharge was performed before and after washing with a broth of Rhodiola rosea.

 In all patients who were washed the wound, after the procedure there was no growth of microorganisms, while after washing with distilled water (control), the growth of microorganisms is preserved.

 All patients who received the Rhodiola rosea preparation inside showed an improvement in their general condition, a decrease in the severity of the general intoxication syndrome, normalization of the temperature reaction and peripheral blood parameters, and, despite taking antibiotics, maintaining adequate immunity.

 The invention is illustrated by the following clinical examples.

 1. Patient P., 45 years old, was admitted on 04/23/95 with a diagnosis of phlegmon of the temporal, infratemporal spaces on the right, orbit OD. The prognosis at admission was unfavorable - there was a high risk of complications in the form of toxic optic dystrophy of the optic nerve, the spread of inflammation to the membranes of the brain and to neighboring cellular spaces. Upon admission to the patient, an operation was performed to drain the focus of purulent inflammation with three external incisions. As a basic therapy, the patient received the antibiotic oxacillin 0.5 to 4 times a day, infusion therapy. For washing the wounds, a 15% decoction of Rhodiola rosea was used. The control was carried out by examination of smears from the wound before and after washing - smears after washing the wound with Rhodiola rosea were sterile. On the third day after admission, the wound cleared of necrotic masses, purulent discharge ceased and 10 days after hospitalization the patient was discharged for outpatient treatment.

 2. Patient G., 29 years old, was admitted for the third time during the year with a diagnosis of furunculosis, abscessed chin furuncle. The patient suffers from furunculosis for 1.5 years, when, after childbirth, pustular eruptions appeared on the face and trunk for the first time. The patient was treated three times in surgical clinics, where she received courses of antibiotic therapy, immunotherapy. On admission, the abscess was drained by external access. As monotherapy, the patient received a 10% extract of Rhodiola rosea orally twice a day for 10 days. In the table. 3 shows the dynamics of indicators of peripheral blood.

 The table shows that the patient returned to normal leukocyte count, appeared eosinophils, significantly differentiated lymphocytes and activated phagocytosis.

 After the course of the drug, the patient was discharged home in satisfactory condition, the wound was completely epithelized. To date, the patient has not noted the recurrence of furunculosis.

 3. Patient S., 53 years old, was admitted March 15, 1995, with a diagnosis of putrefactive necrotic phlegmon of the bottom of the oral cavity. The condition of the patient upon admission was assessed as extremely difficult, the prognosis of the course of the disease was unfavorable - the risk of developing odontogenic contact mediastinitis is high. Upon admission to the patient, the operation of draining the focus of purulent inflammation with two external incisions was performed. In the postoperative period, he received ampicillin 1.0 4 times a day and twice a day 10% extract of Rhodiola rosea, in addition, the wound was washed twice a day with 15% broth of Rhodiola rosea. Bacteriological examination revealed the association of Staph.aureus + E. Coil pathogens. In the early postoperative period, the patient's condition improved significantly, blood pressure stabilized, and body temperature returned to normal. On the second day, the process of cleansing the wound from necrotic masses began, on the third day granulations appeared and began to actively vegetate, and on the ninth day the patient was discharged from the hospital. In the table. 4 provides data on the dynamics of peripheral blood parameters.

 The table shows that this patient in the early stages of normalization of the number of leukocytes, there is an increase in the number of lymphocytes and increased differentiation, activation of phagocytosis.

 Thus, Rhodiola rosea, along with immuno-absorbing, stimulating and adaptogenic effects, also has antibacterial activity with low allergenic properties and can be used as an antibacterial agent. The use of Rhodiola rosea in combination with antibiotics increases the effectiveness of the treatment of purulent-inflammatory diseases.

Claims (1)

 The use of a decoction and / or extract of Rhodiola rosea as an antibacterial agent.

Images